CLINICAL_TRIALS
trial_result
· 2018-10-15
Clinical Trial Update: Brilinta Taiwan Post Approval Safety Study [Phase 4]
Summary
Phase 4 post-approval safety study for Brilinta in patients with non-ST-elevation myocardial infarction has completed with results posted in 2018.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: AstraZeneca | Conditions: Non ST-elevation Myocardial Infarction | Phase 4 | Status: COMPLETED | Results posted: 2018-10-15